Identifying novel pathways at the interface of immunity and metabolism

About Us

Landos Biopharma is a late clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, omilancor (BT-11), is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. In 2021, the Company reported final results from a Phase 2 proof-of-concept trial of omilancor in patients with mild-to-moderate ulcerative colitis (UC) and is preparing to initiate a global pivotal Phase 3 program of omilancor in UC patients. Additionally, Landos initiated a Phase 2 trial of omilancor for the treatment of moderate-to-severe Crohn’s disease (CD) in May 2021.

The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm for autoimmune disease.

Management Team

Tim M. Mayleben

Interim President & Chief Executive Officer

Read More about Tim M. Mayleben
simon lichtiger headshot

Simon Lichtiger, M.D.

Vice President, Clinical Development and Medical Affairs

Read More about Simon Lichtiger, M.D.

Board of Directors

Tim M. Mayleben

Interim President & Chief Executive Officer

Read More about Tim M. Mayleben

Chris Garabedian

Chairman

Read More about Chris Garabedian

Fred Callori

Xontogeny, Perceptive Advisors

Read More about Fred Callori

Tiago Girão

CFO of Proteovant Therapeutics

Read More about Tiago Girão

Roderick Wong, M.D., MBA

Managing Partner, RTW Investments

Read More about Roderick Wong, M.D., MBA

Roger Adsett

Chief Operating Office of Insmed, Inc.

Read More about Roger Adsett

Clinical Advisory Board